Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C.S. Tam
An Undetectable Pb MRD Status Should Be the Therapeutic Goal With Venetoclax Therapy in Relapsed/ Refractory CLL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the Duo Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
An Improved Benefit-Risk Profile of Duvelisib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received 2 or More Prior Therapies
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Head-To-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients With Waldenström Macroglobulinemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
